文献速递糖尿病

达格列净对2型糖尿病患者尿液代谢组的影响

Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

质子核磁共振代谢组分析显示,达格列净显著改变尿液代谢谱,而胰岛素未引起类似变化,提示其肾脏保护作用可能不依赖降糖效应。

要点

  • 达格列净显著改变2型糖尿病患者尿液代谢组,且不依赖血糖改善。
  • 尿酮体、乳酸、支链氨基酸、甜菜碱、肌醇等代谢物显著升高。
  • 多数代谢变化可能有益,或有助于解释达格列净的肾脏保护作用。

核心结论

  • 达格列净以不依赖降糖的方式显著影响2型糖尿病患者尿液代谢组,多数变化可能有益并参与其肾脏保护作用。

主要发现

  • 多变量分析显示达格列净显著改变尿液代谢组(R2X=0.819,R2Y=0.627,Q2Y=0.362,P<0.001),胰岛素未引起显著改变。
  • 达格列净治疗后尿酮体、乳酸、支链氨基酸(P<0.001)、甜菜碱、肌醇(P<0.0001)和N-甲基乙内酰脲(P<0.005)显著升高。
  • 尿丙氨酸、肌酸、肌氨酸和柠檬酸也升高(P<0.0001、P<0.0001和P<0.0005),而鹅肌肽降低(P<0.0005)。

临床怎么用

  • 达格列净的肾脏保护机制可能部分通过尿液代谢物改变实现,临床关注其代谢效应时需考虑不依赖降糖的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Inhibitors of sodium-glucose cotransporters-2 have cardio- and renoprotective properties. However, the underlying mechanisms remain indeterminate. OBJECTIVE: To evaluate the effect of dapagliflozin on renal metabolism assessed by urine metabolome analysis in patients with type 2 diabetes. DESIGN: Prospective cohort study. SETTING: Outpatient diabetes clinic of a tertiary academic center. PATIENTS: Eighty patients with hemoglobin A1c > 7% on metformin monotherapy were prospectively enrolled. INTERVENTION: Fifty patients were treated with dapagliflozin for 3 months. To exclude that the changes observed in urine metabolome were merely the result of the improvement in glycemia, 30 patients treated with insulin degludec were used for comparison. MAIN OUTCOME MEASURE: Changes in urine metabolic profile before and after the administration of dapagliflozin and insulin degludec were assessed by proton-nuclear magnetic resonance spectroscopy. RESULTS: In multivariate analysis urine metabolome was significantly altered by dapagliflozin (R2X = 0.819, R2Y = 0.627, Q2Y = 0.362, and coefficient of variation analysis of variance, P < 0.001) but not insulin. After dapagliflozin, the urine concentrations of ketone bodies, lactate, branched chain amino acids (P < 0.001), betaine, myo-inositol (P < 0001), and N-methylhydantoin (P < 0.005) were significantly increased. Additionally, the urine levels of alanine, creatine, sarcosine, and citrate were also increased (P < 0001, P <0.0001, and P <0.0005, respectively) whereas anserine decreased (P < 0005). CONCLUSIONS: Dapagliflozin significantly affects urine metabolome in patients with type 2 diabetes in a glucose lowering-independent way. Most of the observed changes can be considered beneficial and may contribute to the renoprotective properties of dapagliflozin.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bletsa E, Filippas-Dekouan S, Kostara C, et al. Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes. J Clin Endocrinol Metab. 2021. PMID: 33592103. doi:10.1210/clinem/dgab086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。